Dr. Lal Path Labs
NSE: LALPATHLAB · ISIN INE600L01024 · Healthcare
₹2,029.30+20.50 (+1.02%)
Monday 9 November, 12:05 IST. Delayed. Source: Yahoo Finance.
Price chart
₹2,029.30 +20.50 (+1.02%) today
The day
- Previous close
- ₹2,008.80
- Open
- ₹2,014.90
- Day high
- ₹2,079.00
- Day low
- ₹1,990.10
Listed on NSE since 23 December 2015.
Key numbers
- Market value
- ₹32,941 Cr
- P/E (trailing)
- 56.50
- EPS (trailing)
- ₹34.87
- Price to book
- 11.99
- Dividend yield
- 1.02%
- Return on equity
- 22.6%
- Debt to equity
- 0.08
- Profit margin
- 19.2%
- Beta
- 0.20
- Volume today
- 2.34 L
- Average volume
- 2.83 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹2,016.64 Cr | ₹238.85 Cr |
| FY24 | ₹2,226.50 Cr | ₹357.74 Cr |
| FY25 | ₹2,461.22 Cr | ₹487.14 Cr |
| FY26 | ₹2,762.77 Cr | ₹504.78 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹874 Cr | ₹192 Cr | +27.6% |
| Q1 FY27Apr–Jun 2026 | ₹798 Cr | ₹170 Cr | +28.0% |
| Q4 FY26Jan–Mar 2026Audited | ₹703 Cr | ₹131 Cr | −15.2% |
| Q3 FY26Oct–Dec 2025 | ₹660 Cr | ₹91 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹731 Cr | ₹151 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹670 Cr | ₹132 Cr | – |
Source: Dr. Lal Path Labs’s results filed with NSE, consolidated (the whole group). Net profit is the share of Dr. Lal Path Labs’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss. EPS before Q3 FY26 is not shown: the share count changed (a bonus, split or merger), so it would not compare.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹526 Cr | ₹489 Cr |
| Investments | ₹527 Cr | ₹423 Cr |
| Inventories | ₹56 Cr | ₹44 Cr |
| Owed by customers | ₹141 Cr | ₹111 Cr |
| Cash and equivalents | ₹344 Cr | ₹243 Cr |
| Total assets | ₹3,458 Cr | ₹3,146 Cr |
| Borrowings | ₹0 | ₹0 |
| Total liabilities | ₹678 Cr | ₹605 Cr |
| Shareholders’ equity | ₹2,745 Cr | ₹2,508 Cr |
Source: Dr. Lal Path Labs’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Dr. Lal Path Labs
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
- Industry
- Diagnostics & Research
- Based in
- Gurugram
- Employees
- 5,206
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Dr. Lal Path Labs in the last day or two.
Dividends and corporate actions
All companies- Interim Dividend - Rs 5 Per Share
Dividend · ex-date 11 November 2026
- Interim Dividend - Rs 5 Per Share
Dividend · ex-date 30 July 2026
- Dividend - Rs 4 Per Share
Dividend · ex-date 25 June 2026 · record date 26 June 2026
- Interim Dividend - Rs 3.50 Per Share
Dividend · ex-date 5 February 2026
- Bonus 1:1
Bonu · ex-date 19 December 2025
- Interim Dividend - Rs 7 Per Share
Dividend · ex-date 7 November 2025
- Interim Dividend - Rs 6 Per Share
Dividend · ex-date 6 August 2025
- Dividend - Rs 6 Per Share
Dividend · ex-date 6 June 2025
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.